These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 36607590)

  • 1. TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors.
    Khosroyani HM; Klug LR; Heinrich MC
    Drugs; 2023 Jan; 83(1):55-73. PubMed ID: 36607590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with
    George S; Blay JY; Chi P; Jones RL; Serrano C; Somaiah N; Gelderblom H; Zalcberg JR; Reichmann W; Sprott K; Cox P; Sherman ML; Ruiz-Soto R; Heinrich MC; Bauer S
    Future Oncol; 2024; 20(27):1973-1982. PubMed ID: 39229786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M; Gelderblom H
    Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
    [No Abstract]   [Full Text] [Related]  

  • 4. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
    Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
    Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
    Naito Y; Nishida T; Doi T
    Gastric Cancer; 2023 May; 26(3):339-351. PubMed ID: 36913072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The management of metastatic GIST: current standard and investigational therapeutics.
    Kelly CM; Gutierrez Sainz L; Chi P
    J Hematol Oncol; 2021 Jan; 14(1):2. PubMed ID: 33402214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
    Goggin C; Stansfeld A; Mahalingam P; Thway K; Smith MJ; Huang P; Jones RL; Napolitano A
    Future Oncol; 2022 Aug; 18(26):2967-2978. PubMed ID: 35880452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.
    Foo T; Goldstein D; Segelov E; Shapiro J; Pavlakis N; Desai J; Yip D; Zalcberg J; Price TJ; Nagrial A; Chantrill L; Burge M; Karapetis CS; Tebbutt N; Roy AC
    Target Oncol; 2022 Mar; 17(2):95-110. PubMed ID: 35290591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
    Huang WK; Wu CE; Wang SY; Chang CF; Chou WC; Chen JS; Yeh CN
    Curr Treat Options Oncol; 2022 Sep; 23(9):1303-1319. PubMed ID: 35976553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment strategies for advanced-stage gastrointestinal stromal tumours.
    Klug LR; Khosroyani HM; Kent JD; Heinrich MC
    Nat Rev Clin Oncol; 2022 May; 19(5):328-341. PubMed ID: 35217782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advanced GIST: Which treatments in 2022?].
    Mas L; Bachet JB
    Bull Cancer; 2022 Oct; 109(10):1082-1087. PubMed ID: 35934543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
    Symcox M; Jones RL
    Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gastrointestinal stromal tumors (GIST)].
    Jaros D; Bozic B; Sebesta C
    Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
    Bauer S; Joensuu H
    Drugs; 2015 Aug; 75(12):1323-34. PubMed ID: 26187774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
    Lee DM; Sun A; Patil SS; Liu L; Rao AV; Trent PT; Ali AA; Liu C; Rausch JL; Presutti LD; Kaczorowski A; Schneider F; Amankulor NM; Shuda M; Duensing A
    Sci Rep; 2022 May; 12(1):8275. PubMed ID: 35585158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs for the treatment of gastrointestinal stromal tumors.
    Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
    Serrano C; Mariño-Enríquez A; Tao DL; Ketzer J; Eilers G; Zhu M; Yu C; Mannan AM; Rubin BP; Demetri GD; Raut CP; Presnell A; McKinley A; Heinrich MC; Czaplinski JT; Sicinska E; Bauer S; George S; Fletcher JA
    Br J Cancer; 2019 Mar; 120(6):612-620. PubMed ID: 30792533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.
    Gounder MM; Maki RG
    Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J
    Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.